A Phase 2, Open Label, Efficacy and Safety Study of Autologous HB-adMSCs for the Treatment of Patients With Multiple Sclerosis
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Hope Biosciences
- 04 Feb 2025 New trial record